A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Other

• Patients unable to provide written informed consent
• Contra-indication according to the respective current German SmPC ("Summary of product characteristics"), as judged by the treating physician
• The patient is currently under active treatment in an investigational study

• Patients with a histological diagnosis of locally advanced/metastatic HR+/HER2- breast cancer. Histological diagnosis does not necessarily origin from metastasis, but must reflect the most recent disease status
• No prior systemic treatment for locally advanced/metastatic disease in the palliative setting
• The treating physician has made the decision to treat the patient
• with ribociclib in combination with an aromatase inhibitor or fulvestrant as initial treatment in first line, or
• endocrine therapy as initial treatment in first line (e.g. letrozole, anastrozole, fulvestrant), or
• chemotherapy as initial treatment in first line (e.g. taxanes, capecitabine, with or without bevacizumab)
• Written informed consent of the patient
• Patient who initiated treatment for first line no longer than 4 weeks (28 days) prior to written informed consent for this study
• Planned treatment is in line with the respective current German SmPC ("Summary of product characteristics")
• Patient is ≥18 years